Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 5;4(3):e10143.
doi: 10.1002/btm2.10143. eCollection 2019 Sep.

Nanoparticles in the clinic: An update

Aaron C Anselmo  1 , Samir Mitragotri  2
Affiliations
Review

Nanoparticles in the clinic: An update

Aaron C Anselmo et al. Bioeng Transl Med. .

Abstract

Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.

Keywords: clinic; clinical translation; clinical trials; drug delivery; nanomedicine; nanoparticles; translational medicine.

PubMed Disclaimer

References

    1. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10‐29. - PMC - PubMed
    1. Krauss AC, Gao X, Li L, et al. FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high‐risk acute myeloid leukemia. Clin Cancer Res. 2019;25(9):2685‐2690. - PubMed
    1. FDA News Release . FDA approves first treatment for certain types of poor‐prognosis acute myeloid leukemia 2017. http://www.fda.gov/news-events/press-announcements/fda-approves-first-tr.... Accessed August 3, 2019.
    1. Feldman EJ, Lancet JE, Kolitz JE, et al. First‐in‐man study of CPX‐351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979‐985. - PMC - PubMed
    1. VYXEOS™ Prescription Drug Labeling. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf. Accessed August 3, 2019.

LinkOut - more resources